Immunogenicity and Safety of a MenACWY-CRM Booster Dose 4-6 Years After Primary Quadrivalent Meningococcal Conjugate Vaccination in Healthy US
Background. Neisseria meningitidis serogroups A, B, C, W, and Y are a leading cause of bacterial meningitis and sepsis worldwide. Infants <1 year, adolescents and young adults are at the highest risk. The US Advisory Committee on Immunization Practices (ACIP) recommends routine MenACWY conjugate vaccination for adolescents at 11-12 years of age, with a booster dose 5 years later. We examined responses to a booster dose of MenACWY-CRM given 4-6 years after primary vaccination with a licensed quadrivalent meningococcal conjugate vaccine (NCT02986854).
Methods. 602 adolescents and adults aged 15-55 years who had received either MenACWY-CRM (N = 301) or MenACWY-D (N = 301) 4-6 years earlier, and a control group of vaccine-naïve participants (N = 102) were enrolled at 37 centers across the US and 701 overall received a single dose of MenACWY-CRM at Day 1, across study groups. Immunogenicity was evaluated pre-vaccination, either 4 or 6 days post-vaccination (sampling subgroups) and 29 days post-vaccination by serum bactericidal activity assay using human complement (hSBA). After vaccination, all participants were to be monitored for 7 days for reactogenicity, 29 days for unsolicited adverse events (AEs), and 6 months for occurrence of medically attended events, AEs leading to withdrawal and serious AEs.
Results. Sufficiency of the immune response to a booster dose of MenACWY-CRM was demonstrated as the lower limit of the 1-sided 97.5% confidence interval for percentages of participants with hSBA seroresponse for each serogroup at 29 days post-vaccination was >75%, both in participants primed with MenACWY-CRM and MenACWY-D. Independent of quadrivalent meningococcal vaccine priming, >93% of participants achieved a seroresponse at day 29 post-booster. By day 6 post-booster, >47% of primed participants achieved hSBA titers ≥1:8 for MenA, >87% for MenC, >93% for MenW and >85% for MenY, and by day 29 almost all primed participants had seroprotective titers across all serogroups. Overall, the vaccine was well tolerated across participants in all 3 groups and no safety concerns were raised.
Conclusion. MenACWY-CRM induced robust boosting in adolescents and adults primed with a quadrivalent meningococcal conjugate vaccine 4-6 years earlier, with an acceptable clinical safety profile.
Funding Methods. An online quantitative survey was fielded among 619 US parents of adolescents aged 16-19 years, recruited from GfK's KnowledgePanel ® in December 2016. Demographics, access to care, decision making, and vaccine use were collected. A population-based weighting method was applied. Four logistic regressions and Classification And Regression Trees (CART) were conducted to examination most influential factors associated with MenB vaccine awareness and utilization.
Results. Of the weighted sample, 57% were unaware of MenB vaccines (Figure 1 ). Results from logistic regression models (Table 1) revealed that awareness was likely associated with gender and race. Parents who obtained a recommendation from HCPs were 4.8 (95% CI: 2.5-9.4) times more likely to vaccinate or intend to vaccinate their adolescent children and 5.7 (95% CI: 2.5-12.9) times more likely have adolescents already vaccinated than those parents who did not receive the recommendation from HCP. Race/ethnicity and insurance type were associated with awareness and vaccine utilization. The results from CART verified that HCPs' recommendation is the most influential factor to predict the vaccination status. Parents' socio-economic status and their relationship with HCPs were among the most influential predictors of awareness of MenB vaccines or interest in learning about MenB vaccines if they were unaware.
Conclusion. MenB awareness and vaccination are associated with parents' socio-economic status and HCPs' recommendation. Even among those unaware, there was a willingness to vaccinate when recommended by an HCP. These data underscore the critical need for robust understanding and consistent implementation of ACIP's Category B recommendation to reduce inequities in MenB vaccine awareness and utilization. Saturday, October 6, 2018: 12:30 PM Background. Serogroup B is the leading cause of invasive meningococcal disease (IMD) in United States. Among 16-23 year olds, particularly for college students, serogroup B (MenB) disease is greater than serogroups C, W, and Y combined. ACIP recommends routine immunization with MenACWY vaccine (Category A) but a non-routine recommendation based on individual clinical decision-making for MenB vaccine (Category B). Contrasting ACIP recommendations may affect how healthcare providers (HCP) prescribe meningococcal vaccines. We aimed to understand HCPs' decision process and vaccination practice pattern to prescribe meningococcal vaccines in relation to their experience and interpretations of ACIP recommendations.
Disparities in Healthcare Providers' Interpretation and Implementation of ACIP's Meningococcal Vaccine Recommendations
Methods. A web-based survey was conducted during August-October 2017 among a nationally representative HCP sample. Univariate analyses were conducted.
Results. Of 529 HCP participants, 436 (82.4%) self-identified as prescribers of MenB only or both meningococcal vaccines, and 93 (17.6%) as prescribers of MenACWY vaccine only (Table 1) . When HCPs were asked to rank the most impactful factor in their decision process, 45% ranked guideline considerations as the highest in their decisions to prescribe MenACWY to 16 year olds, followed by disease related factors (36%). For MenB vaccine, 40% ranked disease related factors as the highest, followed by guideline considerations (37%); however, contrasting to MenACWY vaccine (45% vs. 24%), there was no difference (37% vs. 38%) regarding how guideline considerations drove the decision to prescribe or not to prescribe MenBvaccine (Table 2) . Overall, HCPs interpreted ACIP's MenACWY recommendation more uniformly than the MenB recommendation (Figure 1 ) with majority interpreting MenACWY vaccine as for everyone, whereas MenB was split into for everyone or for a sub-group based on risk factors; ~1/4th of MenACWY only prescribers did not know how to interpret the MenB recommendation.
Conclusion. The ACIP MenB vaccine recommendation is inconsistently interpreted across HCPs and might affect their decision process and vaccination practice pattern to prescribe meningococcal vaccines resulting in disparities in access to MenBvaccines.
